Transmedics Group Inc

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TransMedics reports stellar Q4 earnings, eyes growth amid operational challenges

TransMedics Group Inc delivered strong financial performance in Q4 2022, driven by robust revenue growth and strategic investments in infrastructure.
While facing margin pressure and operational challenges, the company's focus on innovation and expansion positions it well for future growth and market leadership.
With a clear roadmap for 2023 and a solid cash position, TransMedics is poised to navigate challenges, capitalize on opportunities, and drive sustainable value creation.

Transmedics reports stellar Q1 results, anticipates growth challenges ahead

Transmedics Group Inc (TMDX) delivered strong financial performance in Q1 2023, driven by the success of the TransMedics NOP and consistent growth in liver and heart cases. Despite facing operational challenges and increased expenses, the company remains optimistic about its growth prospects and revenue guidance for 2023. Strategic focus on product availability and infrastructure expansion bodes well for future success.

TransMedics reports record Q2 revenue, eyes transplant logistics expansion

TransMedics Group Inc's Q2 earnings call highlighted robust performance, strategic acquisitions, and ambitious growth targets, underpinning their market position.
While facing challenges in profitability and operational timelines, the company's focus on enhancing logistics and expanding revenue streams signals a promising trajectory.
Investors should monitor TransMedics' execution of growth plans, including the aviation fleet expansion and next-gen lung system integration, for future value creation.

TransMedics reports stellar Q3 results, eyes expansion and efficiency

TransMedics Group Inc's Q3 earnings call highlighted exceptional revenue growth, operational achievements, and strategic acquisitions, positioning the company for continued success.
The company's focus on revenue diversification, operational efficiency, and innovation underscores its commitment to driving growth and improving patient outcomes.
Despite challenges in growth analysis and program limitations, TransMedics remains optimistic about future opportunities and is poised to capitalize on market trends.

Transmedics Group reports robust earnings, eyes growth in transplant services

Transmedics Group Inc (TMDX) delivered strong financial results in Q4 and full-year 2023, showcasing revenue growth and operational profitability, despite margin pressures.
The company's focus on expanding transplant logistics services, addressing concerns, and presenting data analysis at conferences highlights its commitment to growth and innovation.
With strategic initiatives planned for 2024, TransMedics aims to drive market share in heart, liver, and lung transplants, capitalize on growth opportunities, and enhance operational efficiency for sustained success.
Confidence in providing cost-effective transplant logistics and plans for equal contribution from all three organs position TransMedics for future growth and market leadership in the transplant industry.

TransMedics reports robust Q1 earnings, eyes global expansion and innovation

TransMedics Group Inc (TMDX) delivered strong Q1 2024 results, with notable revenue growth and margin improvement, setting the stage for continued expansion and innovation in the transplant industry.
The company's strategic focus on next-gen technology platforms, new clinical programs, and international market expansion positions it well for sustained growth and leadership in the sector.
While facing challenges in margin improvement and market acceptance, TransMedics has the opportunity to leverage its strengths in product innovation and global appeal to drive future success.

Transmedics Group Inc (TMDX) excels in Q2, eyes clinical program growth

Transmedics Group Inc delivered a stellar performance in Q2 2024, marked by robust revenue growth, operational profitability, and positive free cash flow.
The company's strategic initiatives to expand the aviation fleet, launch new clinical programs, and raise revenue guidance demonstrate a focus on innovation and growth.
While facing challenges in program launches and market competition, Transmedics remains well-equipped to leverage opportunities for market expansion and sustained success.

Transmedics reports robust Q3 performance amidst market challenges

Transmedics Group Inc delivered strong financial results in Q3 2024, driven by robust U.S. sales growth and strategic investments in infrastructure and technology.
While facing challenges with declining transplant volumes and margin pressures, the company remains focused on long-term growth initiatives and maintaining operational efficiency.
Opportunities lie in optimizing international sales, exploring new growth avenues, and leveraging innovative technologies to drive future revenue and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Recently, U.S. stock markets have been more volatile than usual. TransMedics stock has surged thanks to revenue that has more than doubled this year.

1 No-Brainer Growth Stock I Can't Wait to Buy Again if the Market Crashes

TransMedics (TMDX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, TMDX crossed above the 20-day moving average, suggesting a short-term bullish trend.

TransMedics (TMDX) Recently Broke Out Above the 20-Day Moving Average

TransMedics Group, Inc. reported 117.9% YoY revenue growth in Q2 2024 and raised full-year guidance significantly, showcasing strong financial performance. Acquisition of Summit Aviation and building the largest transplant logistics network in the US enhances its competitive moat. Conservative guidance, potential for continued revenue and margin expansion, and robust management led by a visionary CEO position, position TransMedics Group for sustained growth.

Betting Big On TransMedics (Q2 2024 Update)

TransMedics reported strong Q2 results, exceeding revenue and EPS estimates, and the company increased full-year guidance by $40 million at the mid-point of the new range. The company continues its beat-and-raise guidance policy, with strong performance in liver and heart transplants driving growth in the second quarter. The formation of the logistics business is increasingly looking like a great decision.

TransMedics: Strong Execution And Management Conservatism Is A Recipe For Success

TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Can TransMedics (TMDX) Run Higher on Rising Earnings Estimates?

Deckers Outdoor

Wingstop

Over the past years, AI and GLP-1 stocks have been the major themes that have drawn the most attention. However, plenty of other investments have been working and flying under the radar in this market.

Q3's Rising Stars: 3 Growth Stocks for Your Must-Watch List

TransMedics Group had a remarkable second quarter, beating revenue estimates and raising guidance. The company's National Organ Care Systems Program is driving growth, with liver revenues up 2.4x and heart revenues doubling year over year. Long-term valuation model predicts significant EPS growth, with potential for the stock to reach $265 a share by 2026, representing 75% upside.

TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy

Independent Bank

Silvercorp Metals

WisdomTree Inc

Yelp

SVM, IBCP, TMDX, WT and YELP have been added to the Zacks Rank #1 (Strong Buy) List on August 2, 2024.

New Strong Buy Stocks for August 2nd

The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, TransMedics (TMDX) Q2 Earnings: A Look at Key Metrics

TransMedics Group reported significant top- and bottom-line improvement in Q2. The company raised its full-year revenue guidance.

Why TransMedics Group Stock Is Soaring Today

Revenue of $114.3 million, a 118% increase year over year. Full-year revenue guidance increased to $425 million to $445 million.

TransMedics Group Raises Full-Year Guidance

TransMedics Group, Inc. (TMDX) Q2 2024 Earnings Call Transcript

TransMedics (TMDX) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to loss of $0.03 per share a year ago.

TransMedics (TMDX) Q2 Earnings and Revenues Top Estimates

ANDOVER, Mass. , July 31, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended June 30, 2024.

TransMedics Reports Second Quarter 2024 Financial Results

ANDOVER, Mass. , July 29, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 44th Annual Growth Conference at the InterContinental Boston Hotel.

TransMedics to Present at the Canaccord Genuity 44th Annual Growth Conference

Get a deeper insight into the potential performance of TransMedics (TMDX) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Wall Street's Insights Into Key Metrics Ahead of TransMedics (TMDX) Q2 Earnings

ANDOVER, Mass. , July 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2024 after market close on Wednesday, July 31, 2024.

TransMedics to Report Second Quarter 2024 Financial Results on July 31, 2024

TransMedics (TMDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

TransMedics (TMDX) Moves to Buy: Rationale Behind the Upgrade

Credo Technology Group Holding Ltd

Marathon Digital Holdings

Rocket Lab USA

Symbotic Inc

In 2024, the fastest-growing stocks have been in the momentum category, led by NVIDIA (NASDAQ: NVDA).

5 Growth Stocks Poised to Grow Faster than NVIDIA Next Year

Viking Therapeutics

Vertex Pharmaceuticals

Vertex Pharmaceuticals could have multiple new blockbusters on the way. Viking Therapeutics is targeting two massive markets -- obesity and NASH.

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030

Intuitive Surgical

United Therapeutics

Medical devices are spearheading the digitalization of healthcare, reports analytics and software development company Luxoft. Specifically, medical devices are “providing accurate diagnoses, effective treatments and personalized care through advanced algorithms and patient data analysis.

The 3 Best Medical Device Stocks to Buy in June 2024

Applied Therapeutics Inc

Insmed

Eli Lilly

As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 4 Health Care Stocks That May Keep You Up At Night This Month

TransMedics (TMDX) Just Reclaimed the 20-Day Moving Average

Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why TransMedics (TMDX) is a Great Choice

Zacks.com users have recently been watching TransMedics (TMDX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

News for Transmedics Group Inc Stock (TMDX)